Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (41-50 of 426) with videos related to

Pageof 43
Sort By:
Diabetes, Obesity & Metabolism|January 30, 2018
Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptinAngelo Avogaro, Gian Paolo Fadini
European Journal of Internal Medicine|March 15, 2026
Discontinuation of incretin-based therapies in obesity: the complexity of a breakupAngelo Avogaro, Gian Paolo Fadini
The Lancet. Diabetes & Endocrinology|March 23, 2026
Revisiting the burden and patterns of myocardial infarction in type 1 diabetesAngelo Avogaro, Gian Paolo Fadini
Expert Review of Endocrinology & Metabolism|February 21, 2019
Role of endothelial progenitor cells in diabetes mellitusAngelo Avogaro, Gian Paolo Fadini
The Lancet. Diabetes & Endocrinology|July 10, 2025
Incretins and the cardiovascular system: bridging digestion with metabolismAngelo Avogaro, Gian Paolo Fadini
Diabetes, Obesity & Metabolism|May 1, 2020
High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?Marta Mazzucato, Paola Fioretto, Angelo Avogaro
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 29, 2005
Mechanisms of endothelial dysfunction in obesityAngelo Avogaro, Saula Vigili de Kreutzenberg
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Monocyte NADPH oxidase subunit p22(phox) and inducible hemeoxygenase-1 gene expressions are increased in type II diabetic patients: relationship with oxidative stressAngelo Avogaro, Elisa Pagnin, Lorenzo Calò
Diabetes Care|July 22, 2016
Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysisEdoardo Mannucci, Ofri Mosenzon, Angelo Avogaro
Diabetes/Metabolism Research and Reviews|January 11, 2018
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapyAngelo Avogaro, Elías Delgado, Ildiko Lingvay
Pageof 43

Showing results (41-50 of 426) with videos related to

Sort By:
Pageof 43
Diabetes, Obesity & Metabolism|January 30, 2018
Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptinAngelo Avogaro, Gian Paolo Fadini
European Journal of Internal Medicine|March 15, 2026
Discontinuation of incretin-based therapies in obesity: the complexity of a breakupAngelo Avogaro, Gian Paolo Fadini
The Lancet. Diabetes & Endocrinology|March 23, 2026
Revisiting the burden and patterns of myocardial infarction in type 1 diabetesAngelo Avogaro, Gian Paolo Fadini
Expert Review of Endocrinology & Metabolism|February 21, 2019
Role of endothelial progenitor cells in diabetes mellitusAngelo Avogaro, Gian Paolo Fadini
The Lancet. Diabetes & Endocrinology|July 10, 2025
Incretins and the cardiovascular system: bridging digestion with metabolismAngelo Avogaro, Gian Paolo Fadini
Diabetes, Obesity & Metabolism|May 1, 2020
High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?Marta Mazzucato, Paola Fioretto, Angelo Avogaro
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 29, 2005
Mechanisms of endothelial dysfunction in obesityAngelo Avogaro, Saula Vigili de Kreutzenberg
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Monocyte NADPH oxidase subunit p22(phox) and inducible hemeoxygenase-1 gene expressions are increased in type II diabetic patients: relationship with oxidative stressAngelo Avogaro, Elisa Pagnin, Lorenzo Calò
Diabetes Care|July 22, 2016
Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysisEdoardo Mannucci, Ofri Mosenzon, Angelo Avogaro
Diabetes/Metabolism Research and Reviews|January 11, 2018
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapyAngelo Avogaro, Elías Delgado, Ildiko Lingvay
Pageof 43